| July 2 |
Abraxis BioScience Announces Plan to Separate Into Two Independent
Public Companies |
| July 2 |
Pro-Pharmaceuticals Terminates Financing Agreement |
| July 2 |
Biogen Idec and Cardiokine Partner to Develop Lixivaptan, a Novel
Vasopressin Antagonist |
| July 2 |
Santhera Licenses Omigapil for Treatment of Rare Neuromuscular
Diseases |
| July 2 |
Novo Nordisk Increases Transparency on Clinical Trials and
Bioethics |
| July 2 |
Novartis Enhances Its Vaccine Pipeline by Gaining Access to
Intercell's Key Technologies and Vaccines Programs |
| July 2 |
Luc Missorten Has Decided to Pursue New Opportunities |
| July 2 |
Intercell and Novartis Form World-leading Strategic Partnership to
Drive Vaccines Innovation |
| July 2 |
Takeda Wins Patent Infringement Litigation on Appeal Against ANDA
Filers for Generic Actos |
| July 2 |
Galapagos Expands Osteoarthritis Alliance with GlaxoSmithKline; GSK
Makes €4.4 Million Equity Investment in Galapagos |
| July 2 |
Karo Bio and Wyeth Extend Research Collaboration |
| July 2 |
Thar Instruments Completes the Acquisition of Berger SFC Business
from METTLER TOLEDO |
| July 2 |
Genzyme Extends Tender Offer to Acquire Bioenvision, Inc. |
| July 2 |
Dong Wha and Procter & Gamble Pharmaceuticals Form Alliance for
Osteoporosis Treatments |
| July 2 |
FDA Finds Consumers Continue to Buy Potentially Risky Drugs Over
the Internet |
| July 2 |
FDA Approves First Generic Versions of Lamisil Tablets |
| July 2 |
FDA Issues a Safety Alert for Omalizumab (Marketed as Xolair |
| July 3 |
Wyeth Begins Marketing and Distributing BeneFIX in Europe |
| July 3 |
Tysabri Recommended by NICE for Use in Highly Active Relapsing
Remitting Multiple Sclerosis in the Final Appraisal Determination |
| July 3 |
Novartis Plans 30% Increase in US Supplies of Fluvirin Influenza
Vaccines and Delivery of 40 Million Doses for 2007/2008 Season |
| July 3 |
Parker Expands Offering for Biotech Market with Acquisition of
Mitos Technologies, Inc. |
| July 3 |
SAVE THE DATE: First International Symposium on Functional and
Clinical Aspects of the Tumour Antigen CA-IX to be held on 14
November 2007 in Brussels |
| July 3 |
Aptilon Announces the Signing of an Important Enterprise Commitment
with Merck & Co. |
| July 3 |
One-to-One Marketing Agency Expert Communications Inc. (ECI) Joins
Omnicom Group Inc.'s Star Marketing |
| July 3 |
Publicis Groupe to Acquire Muraglia, Calzolari & Associati |
| July 5 |
Increase in Prescription Drug Cost Sharing Associated with Lower
Rates of Drug Treatment, Adherence |
| July 5 |
Researchers Identify Genetic Mutation That May Alter Patients'
Response to Cancer Therapeutics |
| July 5 |
Genaera Discontinues Lomucin in Cystic Fibrosis and Squalamine in
Prostate Cancer Studies |
| July 5 |
ESMO Conference 5-8 July 2007, Lugano, Switzerland - Press Program |
| July 5 |
Head of Innovative Medicines Initiative at the European Commission
to Deliver Keynote Address at ICR European Conference in November |
| July 5 |
From HR towards Talent Management |
| July 5 |
Quintiles to Add Jobs, Consolidate Atlanta Facilities |
| July 6 |
Squeeze Out of Merck Serono Shares Successfully Completed |
| July 6 |
Advanced Medical Optics Confirms $75 Per Share Proposal to Acquire
Bausch & Lomb |
| July 6 |
Bausch & Lomb Receives Acquisition Proposal from Advanced
Medical Optics for $75.00 Per Share in Cash and AMO Stock |
| July 6 |
Medivir Announces Bristol-Myers Squibb has Terminated Their
Agreement for the Development of Medivir's Preclinical Polymerase
Inhibitor, MIV-170 |
| July 6 |
FDA - MedWatch - Merck Recalls 3 Lots Of Invanz (ertapenem sodium)
Injection Because The Product May Contain Broken Glass Pieces In
The Reconstituted Solution For Injection |
| July 6 |
Lorus Therapeutics Announces Revised Closing Date for Proposed Plan
of Arrangement |
| July 6 |
FDA-MedWatch- Rocephin (ceftriaxone sodium)- Contraindications,
Warnings, Precautions, Adverse Reactions, Dosage And Administration
Sections of Labeling Revised |
| July 6 |
Pharma Bloggers Challenge “the Girl from Google”,
Critique Relationship Between Pfizer and CROs |
| July 6 |
Leading Academics and Industry Leaders to Keynote at Dedicated
Co-Crystals Conference |
| July 9 |
Roche and Alnylam Form Major Alliance on RNAi Therapeutics |
| July 9 |
Novavax Licenses Wyeth's Virus-Like Particle Technology |
| July 9 |
Bosch Group Acquires Pharmatec |
| July 9 |
Pfizer Recommends Rejection of Mini-Tender Offer by TRC Capital
Corporation |
| July 9 |
Publicis Groupe Acquires 49.32% of Business Interactif’s
Capital To File a Mixed Tender Offer for Remaining Shares |
| July 9 |
Court Rules in Favor of ARIAD and Co-Plaintiffs in Lilly
NF-(kappa)B Patent Infringement Lawsuit: Patent Found Valid and
Enforceable |
| July 10 |
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin
GR In Postherpetic Neuralgia |
| July 10 |
High Court in Dublin Rules in Pfizer's Favor in Patent Case,
Lipitor Protected from Generic Competition until 2011 |
| July 10 |
Bausch & Lomb Files Preliminary Proxy Statement for Merger
Agreement with Warburg Pincus |
| July 10 |
DynoChem Extends Software Agreement with Bristol-Myers Squibb |
| July 10 |
ReGen Biologics To Exhibit at 2007 AOSSM Annual Meeting |
| July 10 |
Epitome Biosystems Initiates Second Partnership with EMD Chemicals
for Commercial Products |
| July 10 |
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model
& Broadening Product Pipeline |
| July 10 |
Karo Bio Updates Status in the Merck & Co., Inc. Collaboration |
| July 10 |
Genzyme Completes Tender Offer to Acquire Bioenvision, Inc. |
| July 10 |
Head of Innovative Medicines Initiative at the European Commission
to Deliver Keynote Address at ICR European Conference in November |
| July 10 |
IBC Expands Coverage of Case Studies and Projects in Preclinical,
Phase 1 and Phase 2 |
| July 10 |
IVT Lab Week Event Combining Method Validation, Laboratory
Compliance and Stability Testing |
| July 11 |
Ventana's Board Unanimously Rejects Roche's Unsolicited Tender
Offer as Inadequate |
| July 11 |
Bausch & Lomb's Greenville, S.C. Solutions Facility Passes FDA
Inspection |
| July 11 |
Lorus Therapeutics Completes Reorganization Resulting in Non
Dilutive Financing |
| July 11 |
inVentiv Health Completes Acquisitions of Chandler Chicco Agency
(CCA) and AWAC |
| July 11 |
New Pain Therapeutics Summit 2007 Announced |
| July 11 |
Health Experts Come Together to Address Pandemic, Avian Influenza,
Outline the Outlook of Infectious Diseases Threats and Strategies
for Containment |
| July 11 |
Roche Says Offer for Ventana Medical Systems, Inc. is Full and Fair |
| July 11 |
Genentech Announces Second Quarter 2007 Results |
| July 12 |
Abbott Announces Termination of Contract With GE |
| July 12 |
Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino
Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost |
| July 12 |
Ariad and Merck & Co., Inc. Announce Global Collaboration to
Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR
Inhibitor - for Cancer |
| July 12 |
Point Therapeutics Update |
| July 12 |
ICON Acquires DOCS International, Expanding Its Contract Staffing
Footprint into Europe |
| July 12 |
Welsh & Katz Successfully Represents Apotex, Inc. in Federal
Circuit Court Decision Against Daiichi |
| July 13 |
Valopicitabine Development Program Placed on Clinical Hold in the
United States |
| July 13 |
Amgen Board Authorizes $5 Billion Increase in Stock Repurchase
Program |
| July 13 |
Campbell Alliance to Co-Chair and Speak at ExL Pharma Pricing and
Reimbursement Conference |
| July 13 |
Premier Research Group Acquisitions Expand Depth and Breadth of
Offerings |
| July 13 |
UCB Announces Registration of Domination and Profit Transfer
Agreement Allowing Full Integration of Schwarz Pharma |
| July 13 |
AXIS Healthcare Communications LLC Acquired by Huntsworth PLC |
| July 13 |
Pharmaceutical Companies Enter the Blogging Ring, Industry Bloggers
Question FDA’s Revitalization Bill, and Michael Retorts to
CNN |
| July 13 |
Jazz Pharmaceuticals Announces Settlement of Government
Investigation |
| July 13 |
New DNA Sequencing Technology Enables Insurance Companies and
Defense Lawyers to Weed Out Fraud in Class-Action Suits |
| July 13 |
Jazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve
Criminal and Civil Allegations in 'Off-Label' Marketing
Investigation |
| July 16 |
Schwarz Pharma and UCB, Inc. Announce U.S. Launch of Neupro
(Rotigotine Transdermal System) for the Treatment of Early-Stage
Parkinson's Disease |
| July 16 |
NicOx Receives Euro 5 Million Milestone From Merck & Co., Inc.
as Drug Candidate Enters Clinic |
| July 16 |
Roche and BioCryst Advance BCX-4208/R3421 Into Phase II Psoriasis
Trial |
| July 16 |
Affymax Announces Phase 3 Development Plan for Hematide |
| July 16 |
Rotateq and Gardasil Adopted by All Immunization Projects of the
Centers for Disease Control and Prevention's Vaccines for Children
Program |
| July 16 |
Urigen N.A., Inc. Completes Reverse Merger With Valentis, Inc. |
| July 16 |
King Pharmaceuticals to Sell Rochester, Michigan Manufacturing
Facility to JHP Pharmaceuticals |
| July 16 |
Northwest Biotherapeutics, Inc. Responds to Media Reports |
| July 16 |
Boston Scientific Announces Agreement to Settle Product Lawsuits |
| July 16 |
IBM Signs $1.4 Billion Global Strategic Outsourcing Agreement With
AstraZeneca |
| July 16 |
Interpublic Launches Mobile Marketing Agency In Joint Venture with
Velti, Leading Mobile Technology Company |
| July 16 |
VioQuest Pharmaceuticals Strengthens Balance Sheet Through Sale of
Chiral Quest Subsidiary and Completion of Private Placement |
| July 17 |
Pharmacopeia Advances First Therapeutic Program With
GlaxoSmithKline |
| July 17 |
Johnson & Johnson Reports 2007 Second-Quarter Results: Sales
Increase of 13.2% and EPS increase of 10.5% Versus a Year Ago;
Excluding Special Charges in 2006, EPS increased 7.1%* |
| July 17 |
Forest Laboratories, Inc. Reports Fiscal First Quarter 2008
Earnings Per Share Of $0.83 |
| July 17 |
Novartis Delivers Strong Performance in First Half of 2007 |
| July 17 |
Public Statement: European Medicines Agency Starts Review of the
Safety of Epoetins |
| July 17 |
Encysive Pharmaceuticals Retains Morgan Stanley to Assist in Review
of Strategic Alternatives |
| July 18 |
Abbott Reports 15.8 Percent Sales Growth in Second Quarter |
| July 18 |
Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year
2007 and 2008 Financial Guidance and Updates Progress on Immediate
Business Priorities |
| July 18 |
Flash Report of the Interim Financial Results for the Fiscal Term
Ended June 30, 2007 |
| July 18 |
Orchestra Therapeutics Discontinues Its HIV Vaccine Development
Program |
| July 18 |
Merck Transfers Abbott Rights for Niaspan Outside the U.S. |
| July 19 |
Wyeth Reports Earnings Results for the 2007 Second Quarter and
First Half |
| July 19 |
Baxter Raises 2007 Earnings Guidance Following Strong Second
Quarter Financial Results |
| July 19 |
Severin Schwan to Succeed Franz B. Humer as Chief Executive of the
Roche Group at the March 2008 Shareholders' Meeting |
| July 19 |
FDA Sends Letter to Doak Dermatologics Regarding Solaraze Detail
Aid |
| July 19 |
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle
Ultracet Patent Litigation |
| July 19 |
Schering-Plough Announces Licensing of Acadesine, an
Investigational Agent Being Studied for Prevention of Complications
From Cardiac Surgery |
| July 19 |
Roche in the First Half of 2007: Strong Performance Continues |
| July 19 |
European Medicines Agency Recommends Acomplia Must Not Be Used in
Patients on Antidepressants or with Major Depression |
| July 20 |
Galapagos Aannounces Milestone in Collaboration with Boehringer
Ingelheim |
| July 20 |
BioXell to Regain Rights to TREM Platform Following Strategic
Decision by Merck & Co., Inc. |
| July 20 |
Meda Enters the US Market Through the Strategic Acquisition of
MedPointe Inc |
| July 23 |
Merck Reports Double-Digit Earnings-Per-Share Growth for Second
Quarter 2007 |
| July 23 |
Pharmaceutical Bloggers Discuss a Scandal at Novartis, Honesty in
Research & Development, and Pfizer’s Struggles with
Earnings and Dtc Advertising |
| July 23 |
Schering-Plough Reports Financial Results for Second Quarter of
2007 |
| July 23 |
Statement of Purdue Pharma Regarding July 20 Proceedings in the
United States District Court for the Western District of Virginia |
| July 23 |
Taro Postpones Shareholder Meetings on Proposed Merger with Sun
until September 25, 2007 |
| July 23 |
European Medicines Agency Recommends Withdrawal of Medicinal
Containing Veralipride |
| July 23 |
WallStreet Research Releases Buy Recommendation for Nymox
Pharmaceutical Corporation |
| July 23 |
Advanced Biotherapy, Inc. Announces Results of Rights Offering |
| July 24 |
Biogen Idec Reports Second Quarter 2007 Results |
| July 24 |
Panacos to Report Second Quarter Results for 2007 |
| July 24 |
eResearchTechnology, Inc. to Announce 2007 Second Quarter Results
on August 2, 2007 |
| July 24 |
Neogen Announces Fourth Quarter 2007 Earnings Webcast |
| July 24 |
Curis to Release Second Quarter 2007 Financial Results and Hold
Conference Call on July 31, 2007 |
| July 24 |
Matrixx Initiatives, Inc. Reports 4% Revenue Growth in the First
Quarter of Fiscal 2008 and Reduced Seasonal Net Loss |
| July 24 |
Edwards Lifesciences Reports Second Quarter Results |
| July 24 |
Cumberland Pharmaceuticals Inc. Announces Estimated Price Range for
Initial Public Offering |
| July 24 |
Amylin Pharmaceuticals Reports Second Quarter Financial Results |
| July 24 |
EXACT Sciences Announces Second Quarter 2007 Results |
| July 24 |
King Pharmaceuticals Announces Date for Release of Second-Quarter
2007 Financial Results and Conference Call |
| July 24 |
Akzo Nobel NV (NL) - Strong operational quarter for the new Akzo
Nobel |
| July 24 |
Lilly Reports Strong Second-Quarter Results; Raises Full-Year Sales
and EPS Guidance |
| July 24 |
Cipher reports second quarter fiscal 2007 results |
| July 24 |
Hemscott News Alert - Ark Therapeutics Group PLC |
| July 24 |
AVANIR Pharmaceuticals Invites Investors to Third Quarter
Conference Call |
| July 24 |
Oriola-KD Corporation's interim report for 1 January - 30 June 2007 |
| July 24 |
Bio-Imaging Technologies to Release Second Quarter 2007 Financial
Results and Host Conference Call on August 8, 2007 |
| July 24 |
HAQ Special Meeting of Stockholders to Vote on Proposed Merger of
HAQ and PharmAthene Postponed |
| July 24 |
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for
Nomination of CCR1 Small Molecule Development Candidate |
| July 24 |
Former MDS Inc. IT Specialist and Spouse Made More Than $1 Million
From Stolen Information About MDS's Impending Merger With Molecular
Devices |
| July 24 |
FDA Advisory Committee Recommends Approval of Evista for the
Reduction of Risk for Invasive Breast Cancer in Two Populations of
Postmenopausal Women |
| July 25 |
IMPAX Achieves Milestone in Efforts to File Delinquent Periodic
Reports |
| July 25 |
Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent |
| July 25 |
Merck & Co., Inc. to Acquire NovaCardia, Inc., to Boost
Clinical Pipeline of Cardiovascular Drug Candidates |
| July 25 |
Merck & Co., Inc. to Acquire NovaCardia, Inc., to Boost
Clinical Pipeline of Cardiovascular Drug Candidates |
| July 25 |
Genzyme Reports Significant Earnings Growth in Second Quarter |
| July 25 |
Q2/2007: Merck Revenues Soar 67% to EUR 1.8 Billion |
| July 25 |
GSK Reports Second Quarter EPS of 24.0p, Up 11% CER (3% Reported);
Share Buy-back Programme Increased to £12 Billion |
| July 25 |
PRA International Enters Into Merger Agreement With Genstar Capital |
| July 25 |
Court Rules In Favor of Sandoz on Toprol Xl Patent Invalidity |
| July 25 |
Cell Therapeutics, Inc. Announces Agreement to Acquire SMi; Gains
Global Rights to Brostallicin, in a New Class of Cancer Killing
Agents |
| July 25 |
Targeted Genetics' Inflammatory Arthritis Phase I/II Trial Placed
on Clinical Hold |
| July 26 |
Shire plc: 2007 Guidance Upgraded as Revenue Growth Accelerates |
| July 26 |
Bristol-Myers Squibb Company Reports Financial Results for the
Second Quarter and First Half of 2007 |
| July 26 |
AstraZeneca: Second Quarter and Half Year Results 2007 |
| July 26 |
Key Business with Prescription Medicines Continues to Boost Growth
at Boehringer Ingelheim |
| July 26 |
Exelixis Retains Right to Develop and Commercialize XL647 |
| July 26 |
Half-year Report 2007: Schwarz Pharma on Track |
| July 26 |
Top Pharmaceutical Websites Visited by Physicians |
| July 26 |
FDA Classifies Baxter's Voluntary Recall Action Regarding Service
Documentation as a Class I Recall |
| July 26 |
Further Questions and Answers on the Follow-up to the Viracept
Recall |
| July 26 |
Aspreva Announces Restructuring Designed to Drive Long-term Growth |
| July 26 |
Hydra Biosciences and Pfizer Global Research & Development Sign
Collaboration Agreement |
| July 26 |
UCB: First Half-Year 2007 Financial Results |
| July 26 |
Cardinal Health Announces Resolution of SEC Investigation; U.S.
Attorney's Office Closes Related Inquiry |
| July 26 |
Ranbaxy and GlaxoSmithKline Enter Into an Agreement to Settle
Valacyclovir U.S. Patent Litigation |
| July 27 |
GlaxoSmithKline and Targacept Form Alliance in Therapeutics for
CNS-related Disorders |
| July 27 |
Point Therapeutics Announces Further Management Reductions |
| July 27 |
IMPAX Announces Ruling Related to Generic Rilutek |
| July 27 |
Zelnorm to be Made Available to US Patients Under Restricted Access
Program |
| July 27 |
Amgen's Second Quarter 2007 Adjusted Earnings Per Share Increased 7
Percent to $1.12 |
| July 27 |
Kyowa Hakko Three-Month Net Sales up 10.8%; Raises Profit Forecasts |
| July 27 |
Development Discontinued for ANA975, an Early Stage Compound for
Treatment of Hepatitis C Virus Infection |
| July 27 |
Ventana Responds to Roche's Unsolicited Tender Offer Extension |
| July 27 |
FDA Permits Restricted Use of Zelnorm for Qualifying Patients |
| July 27 |
FDA Statement on Gene Therapy Clinical Trial |
| July 27 |
Public Statement on Trudexa (adalimumab) - Withdrawal of the
Marketing Authorisation in the European Union |
| July 27 |
In Pharma Blogs This Week: A Viagra TV Spot is Critiqued,
GlaxoSmithKline is Candid About Alli, and More About the Novartis
Whistleblower |
| July 27 |
Diabetes Drugs Increase Risk of Heart Failure, Research Shows |
| July 30 |
Bristol-Myers Squibb and ImClone Systems Significantly Expand
Erbitux Clinical Development Program |
| July 30 |
GlaxoSmithKline Presents Avandia Data To FDA |
| July 30 |
BioWa Introduces its Second Technology to Dramatically Enhance
Antibody Effector Function and the Launch of AccretaMab Platform |
| July 30 |
Urigen Pharmaceuticals, Inc., formerly Valentis, Inc. Announces
Name Change and New Stock Symbol |
| July 30 |
Caliper Life Sciences Develops Customized Transfection System for
Boehringer Ingelheim |
| July 30 |
OSG Norwich Pharmaceuticals Purchased by AFI Partners |
| July 31 |
Johnson & Johnson Plans to Improve Overall Cost Structure,
While Continuing to Invest in Opportunities for Sustained
Profitable Growth |
| July 31 |
ImClone Systems Reports Second Quarter 2007 Financial Results |
| July 31 |
Takeda Responds to the FDA Advisory Committee Recommendation |
| July 31 |
FDA Advisory Panel Votes 22 to 1 for Avandia to Remain Available to
Patients in the US |
| July 31 |
Biota Raises Relenza Claim to A$564 - A$704 Million (US$485 -
US$605 Million) |
| July 31 |
Neuren to Obtain Late Stage Compound Through Hamilton
Pharmaceuticals Acquisition |
| July 31 |
Termination of Product Marketing Collaboration Between
Sanofi-Aventis and Chugai in Japan |
| July 31 |
EMEA Completes the Review of Recombinant Factor VIII Products and
Development |
| July 31 |
Interpublic Completes Two Major Transactions in Key Growth Market |
